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Osteoarthritis is a severe, debilitating disease that affectsthe whole joint organ and is hallmarked by cartilagedegeneration and synovial hypertrophy. As of 2019,
osteoarthritis is estimated to affect 528 Million people worldwide
and be the 15th leading cause of years lived with disability1. The
lifetime risk of developing symptomatic knee and hip osteoar-
thritis is estimated to be 45 and 25%, respectively2,3, and is on an
upward trajectory commensurate with rises in obesity and the
ageing population. Between 2010 and 2019, the global prevalence
of osteoarthritis and the resulting years lived with disability have
both risen by 27.5%1. In 2013, osteoarthritis cost the United
States $304 Billion4 and was the second most costly health con-
dition treated at US hospitals, accounting for 4.3% of the com-
bined costs for all hospitalisations5. Osteoarthritis-associated
reduced physical activity results in a standardised all-cause
mortality ratio of 1.55 (95% confidence interval 1.41 to 1.70) for
its sufferers versus the general population6. Disease management
focusses on alleviating pain, and in end-stage disease the only
treatment is joint replacement surgery, emphasising the clear and
urgent need to develop new therapies. To achieve this, we need to
improve our understanding of the underlying molecular
pathophysiology.
Epidemiological risk factors for the disease have been well-
established and include older age, female sex, obesity, joint
morphology and injury, and family history. The heritability of
osteoarthritis has been estimated to range between 40 (for knee
osteoarthritis) and 60% (for hip osteoarthritis)7. Genome-wide
association studies (GWAS) have identified ~90 robustly-
replicating risk loci8. However, the molecular landscape of
osteoarthritis-relevant tissue has not been similarly characterised
by large-scale efforts such as the GTEx9, ENCODE10 and Road-
Map Epigenomics11 projects.
In this work, we perform a deep characterisation of the tran-
scriptional and proteomic landscape of disease in chondrocytes
and synoviocytes extracted from primary joint tissue of osteoar-
thritis patients. We define molecular quantitative trait loci,
identify likely effector genes for GWAS signals, characterise
molecular features of cartilage degradation and highlight drug
development and repurposing opportunities through analysis of
transcriptional signature changes.
Results
Generation of human joint tissue molecular profiles. We col-
lected and characterised low-grade (intact; preserved) and high-
grade (highly degraded; lesioned) cartilage, and synovial tissue
from patients undergoing joint replacement for osteoarthritis (see
Methods). The availability of paired low-grade and high-grade
cartilage samples enables the comparison between these two
disease states in affected primary tissue within the same indivi-
dual, with high-grade cartilage showing more advanced cartilage
degradation. All three tissues were profiled by RNA sequencing,
and cartilage samples were additionally profiled by quantitative
proteomics (Fig. 1 and Supplementary Fig. 1). We generated
genome-wide genotype data from peripheral blood to define
molecular quantitative trait loci (molQTLs) in each tissue type
and omics level.
Molecular QTLs in osteoarthritis tissues. Identification of
molecular QTLs can provide a better understanding of the
transcriptional regulation of key cell types across disease stages.
We identified cis expression QTLs (cis-eQTLs) for 1891 genes in
at least one tissue (Fig. 2), with high correlation of effects across
the tissues studied (Supplementary Fig. 2). The direction of effect
was concordant across all cis-eQTLs detected in both low-grade
and high-grade cartilage. We identified cis protein QTLs (cis-
pQTLs) for 38 genes in at least one tissue, with a similarly strong
correlation across low-grade and high-grade cartilage (Supple-
mentary Figs. 3, 4 and Supplementary Note 1).
Differential genetic regulation of gene expression. We identi-
fied differential regulation of gene expression between high-grade
and low-grade cartilage, with 172 variants showing strong evi-
dence for an eQTL effect in one tissue grade (posterior probability
>0.9), but not in the other (posterior probability <0.1), termed
‘differential eQTLs' (Fig. 2, Supplementary Figs. 5, 6, and Sup-
plementary Data 1). We detected 32 genes with differential eQTLs
(Supplementary Data 1). These genes function in the regulation
of gene expression (high-grade eQTL: HOXB2, IFITM3,
EIF2B3TRAF2, HLCS, APBA1, HLX; low-grade eQTL: EARS2,
TCEB1, USP16), nervous system development (high-grade eQTL:
HOXB2, CRLF1, EIF2B3, APBA1, HLX, NEGR1, ARGHAP11B;
low-grade eQTL: SZT2, NRN1), response to stress (high-grade
eQTL: IFITM3, EIF2B3, TRAF2, ICAM3; low-grade eQTL: PNKP,
SZT2, REV1, USP16), immune response (high-grade eQTL:
IFITM3, IL4I1, CRLF1, TRAF2, ICAM3, HLX), cell adhesion
(high-grade eQTL: TRAF2, ICAM3, APBA1, HLX, NEGR1) and
catabolic processes (high-grade eQTL: IL4I1, TRAF2, WDR91,
HAAO; low-grade eQTL: USP16). For most of these processes,
some genes with differential eQTLs show gain of genetic reg-
ulatory associations in high-grade cartilage, while others show
loss of such associations compared to low-grade cartilage, sug-
gesting a broader rewiring of regulatory processes (see Supple-
mentary Note 2). Sixteen genes have differential eQTLs located in
a regulatory region.
Co-localisation of GWAS signals and molecular QTLs in dis-
ease tissue. Having established these cell- and disease stage-
specific maps of molecular QTLs, we used them to identify
effector genes driving GWAS signals, the majority of which reside
in non-coding sequence. Co-localisation analysis can indicate
whether the same variant underpins association with both disease
and gene expression levels. We found strong evidence for co-
localisation of five osteoarthritis signals with cartilage molQTLs
for ALDH1A2, NPC1, SMAD3, FAM53A and SLC44A2 (Table 1,
Fig. 3, and Supplementary Fig. 7). In all five instances, the GWAS
index variant is non-coding. In three cases (ALDH1A2, SMAD3
and SLC44A2), the likely effector gene is the one closest to the
lead variant. For the NCP1 and FAM53A loci, the lead variants
reside in introns of the TMEM241 and SLBP genes, 141 and 18 kb
away from the likely effector gene, respectively.
Molecular hallmarks of cartilage degradation. To identify
molecular signatures associated with disease severity, we char-
acterised gene expression and protein abundance differences
between high-grade and low-grade cartilage in the largest sample
set to date. We detected significant expression differences for
2557 genes and abundance differences for 2233 proteins at 5%
false discovery rate (FDR) (Supplementary Figs. 8, 9, and Sup-
plementary Notes 3, 4). A total of 409 genes (Supplementary
Data 2) demonstrated significant differential expression at both
the RNA and protein levels, lending robust cross-omics evidence
for their involvement in disease progression. In keeping with
previous smaller-scale reports12–14, extracellular matrix (ECM)-
receptor interaction was the primarily activated pathway in high-
grade compared to low-grade cartilage (Supplementary Note 5,
Supplementary Fig. 10, and Supplementary Data 3).
We used an independent, previously published analysis of RNA
sequencing data from 35 osteoarthritis patients15 to replicate the
observed molecular differences between high-grade and low-
grade cartilage (within the power constraints of the smaller
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replication set). Of the differentially expressed genes and proteins,
65.9 and 68.3% showed a concordant direction of effect in
the replication data, respectively (both Fisher’s p < 10−10,
Supplementary Data 4). This concordance increased to 77.9%
for genes with cross-omics concordant differential expression in
this study, indicating additional robustness afforded by cross-
Fig. 1 Study design leveraging multi-omics profiling from osteoarthritis patient tissues. We examined the molecular characteristics of osteoarthritis by
profiling mRNA and proteins from low-grade cartilage, high-grade cartilage and synovium tissue of over 100 patients undergoing total joint replacement for
osteoarthritis, and combining these data with patient genotypes. We identified genetic variants influencing mRNA or protein levels, several of which co-
localise with genetic risk variants for osteoarthritis. We also identified molecular markers of cartilage degeneration, creating a gene expression profile of
degeneration, and shortlisting existing drugs or compounds that reverse this profile in cell experiments.
Fig. 2 Molecular QTLs in osteoarthritis disease tissue. a eQTL overlap between tissues, for a total of 1891 genes with a least one eQTL (left) and 219,709
eQTL gene-variant pairs (right). 49% of detected eQTLs are not tissue-specific. b An example of differential QTL effect: a molecular QTL present in high-
grade, but not low-grade cartilage (posterior probability m > 0.9 and m < 0.1, respectively), or vice versa. The boxplots show expression (residuals after
regressing the normalised expression data on the 15 PEER factors, sex and array) at 25th to 75th percentiles, with centre at the median and whiskers
extend to 1.5 times the interquartile range. NES FastQTL normalised effect size, P FastQTL association P value, n number of individuals included in the
analysis for each genotype. c Genes with ≥5 differential eQTL variants (all genes see Supplementary Data 1).
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omics data integration. We found significantly higher concor-
dance where replication power was highest (88.5% for genes with
cross-omics higher expression in high-grade cartilage, compared
to 66.7% for genes with cross-omics lower expression in high-
grade cartilage, Fisher’s p= 8.6 × 10−6, Supplementary Data 4).
Differentially expressed genes with genetic associations.
Ninety-one of the genes with significantly different expression
profiles between high- and low-grade cartilage were also asso-
ciated with genetic risk of osteoarthritis (i.e. among the 238 genes
with gene-level significant association in a recent meta-analysis8;
Table 1 Osteoarthritis GWAS signals with high posterior probability for co-localisation with molecular QTLs.
GWAS varianta rs10502437 rs11732213 rs12901372 rs1560707 rs4775006
Osteoarthritis phenotype All Hip/Knee Hip All Knee
Risk allele frequency 0.6 0.81 0.53 0.37 0.41
Odds ratio 1.03 1.06 1.08 1.04 1.06
P value 2.50 × 10–8 8.81 × 10–10 3.46 × 10–11 1.35 × 10–13 8.40 × 10–10
Risk allele A T C T A
Gene NPC1 FAM53A SMAD3 SLC44A2 ALDH1A2
Risk allele effect on gene expression decrease decrease decrease increase increase
aSignals are denoted by their lead variants.
Fig. 3 GWAS and molecular QTL P values in regions with co-localisation of the associations. GWAS and molecular QTL P values in regions with co-
localisation of the associations. PP4 posterior probability for co-localisation. a NCP1 eQTLs in high-grade cartilage (b) SLC44A2 eQTLs in high-grade
cartilage (c) FAM53A eQTLs in low-grade cartilage (d) ALDH1A2 pQTLs in low-grade cartilage (e) SMAD3 eQTLs in high-grade cartilage. For NPC1 and
SMAD3, Supplementary Fig. 7 shows co-localisation with low-grade cartilage molecular QTLs.
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Supplementary Data 5). A total of 54 genes also showed con-
cordant molecular differences in the independent replication
dataset, providing further evidence for the potential involvement
of these genes in osteoarthritis disease processes. For example,
variants in ALDH1A2 are associated with knee osteoarthritis, and
we found significantly higher ALDH1A2 gene expression and
lower protein abundance in high-grade cartilage (suggesting a
potential role for post-transcriptional regulation for this gene).
For SLC39A8, the GWAS signal was fine-mapped with posterior
probability of 0.999 to a single missense variant predicted to be
possibly deleterious by PolyPhen-216, and the gene demonstrated
higher expression levels in high-grade cartilage.
Candidate therapeutic compounds and drug targets. Having
characterised the molecular differences between low-grade and
high-grade cartilage in osteoarthritis, we sought to identify
compounds capable of reversing these changes.
Using in vitro drug screen data from ConnectivityMap17, we
identified 19 compounds that induced strong opposing gene
expression signatures, reducing the expression of genes with
cross-omics higher expression in high-grade cartilage (Table 2,
Supplementary Data 6, and Supplementary Note 6). Several of
these compounds foster known biological relevance to osteoar-
thritis, including the oestrogen receptor agonists diethylstilbestrol
and alpha-estradiol, consistent with established epidemiological
data showing an association between osteoarthritis and oestrogen
deficiency18. Although studies of oestrogen therapy for osteoar-
thritis have been inconclusive19,20, this screening approach could
facilitate further refinement of existing drug groups and allow
more focussed investigational molecule development.
Further notable examples of compounds with the potential to
reverse molecular changes include IB-MECA, VEGF-receptor-2-
kinase-inhibitor-IV and nornicotine. IB-MECA is used as an anti-
inflammatory drug in rheumatoid arthritis, and has been shown
to prevent cartilage damage, osteoclast/osteophyte formation and
bone destruction in a rat model of chemically-induced osteoar-
thritis21. VEGF-receptor-2-kinase-inhibitor-IV is a VEGF recep-
tor inhibitor. VEGF modulates chondrocyte survival during
development, is essential for bone formation and skeletal growth,
and dysregulated in osteoarthritis22. A VEGFR2 kinase inhibitor
has demonstrated therapeutic potential in mice23. Nornicotine is
a demethylated derivative of nicotine found in plants, and there is
a well-established epidemiological inverse relationship between
smoking and osteoarthritis8,24. Thus, synthetic nicotine deriva-
tives may have a candidate role in osteoarthritis prevention.
We further identified 36 genes for which knock-down or
overexpression has the potential to reduce the molecular
differences between high-grade and low-grade cartilage (Supple-
mentary Data 6), for example knock-down of IL11. IL11 is a
cytokine with a key role in inflammation, and several therapeutics
that inhibit IL11 signalling are in development against a range of
inflammatory and fibrotic diseases25,26. Variation in IL11 is
associated with increased risk of hip osteoarthritis8, and the gene
is upregulated in osteoarthritis knee tissue27, showing the most
significant upregulation in high-grade cartilage in the indepen-
dent replication dataset15 (22.8-fold higher expression, FDR=
1.5 × 10−20). These findings provide strong supportive evidence
for downregulation of IL11 as a potential therapeutic intervention
for osteoarthritis.
Discussion
To date, deep molecular profiling of cells of relevance to
osteoarthritis has been absent from large-scale efforts such as
GTEx, ENCODE and RoadMap, in part because of the challenges
associated with low cellularity and high ECM content of
cartilage28,29. Here, we address this gap by the systematic study of
paired low-grade and high-grade cartilage and synovium tissues
from 115 patients with osteoarthritis to provide the first deep
molecular QTL map of cell types directly involved in disease.
These data are made publically available (see Data availability).
We identify genotype-dependent, divergent patterns of gene
regulation between diseased and healthy cartilage, and between
cartilage and synovium, that underline the biological specificity of
disease stage and cell type when investigating regulatory variant
function.
The co-localisation of GWAS signals and molecular QTLs in
disease tissue helps pinpoint the identity of causal genes for
hithert unsolved association signals. A previous study8 examined
the co-localisation of osteoarthritis GWAS signals with eQTLs
from the GTEx resource9, which does not include cartilage.
Several osteoarthritis GWAS signals were found to co-localise
with eQTLs in only 1 or 2 of 53 tissues (e.g. ALDH1A2: ovary and
tibial artery, SMAD3: skeletal muscle; SLC44A2: adrenal gland),
without clear transferability of results to disease-relevant tissue.
Here, we provide robust evidence that these three GWAS signals
co-localise with molecular QTLs in primary cartilage. This
availability of molQTL data from chondrocytes and synoviocytes
offers a resource that will enable the resolution of further genetic
association signals emerging from ongoing large-scale efforts in
osteoarthritis (e.g. https://www.genetics-osteoarthritis.com) and
further traits of musculoskeletal relevance, in which these cell
types are of importance.
The strong correlation between RNA and protein level sig-
natures within cell type and disease state and the contrast
Table 2 Compounds with strongest evidence for inducing gene expression signatures that counter differences between high-
grade and low-grade cartilage, based on data from ConnectivityMap17 and the clue.io platform.
Namea Description DE targetsb
Emetine protein synthesis inhibitor RPS2 (P+)
Rucaparib PARP inhibitor PARP2 (R−)
Alpha-estradiol oestrogen receptor agonist KCNMA1 (R−, P−)
VEGF-receptor-2-kinase-inhibitor-IV VEGFR inhibitor
IB-MECA adenosine receptor agonist, granulocyte colony stimulating factor agonist
Diethylstilbestrol oestrogen receptor agonist, chloride channel blocker
KIN001-220 Aurora kinase inhibitor
SB-216763 glycogen synthase kinase inhibitor GSK3B (R+, P+), CDK2 (P−)
RHO-kinase-inhibitor-III[rockout] ROCK inhibitor IMPDH2 (P−)
Nornicotine acetylcholine receptor agonist
aThe 10 compounds with strongest evidence based on median of cell lines are shown; full results see Supplementary Data 6.
bDrug targets as listed in ConnectivityMap with differential expression between high-grade and low-grade cartilage on RNA (R) or protein (P) level, ‘+' and ‘−' indicate higher or lower expression high-
grade cartilage, respectively.
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between disease states provides both strong internal consistency
and with previous observations of ECM remodelling by chon-
drocytes in an inflammatory environment as a key modifiable
molecular signature in the degeneration process30,31. We further
demonstrate the external validity of these hallmark signatures by
showing good concordance with publically-available RNA-seq
data from a smaller, independent, human osteoarthritis cohort15,
particularly for genes whose expression is increased in high-grade
cartilage.
On a related theme, our identification of an association
between 91 established osteoarthritis variants and disease state,
cell-specific gene expression and protein profiles highlights the
value of integrating multi-omics data with genetic association
summary statistics to identify likely effector genes for GWAS
signals, and hence targets for development of new therapies. The
subsequent ConnectivityMap analyses built upon this theme to
identify molecules with potential clinical application to reverse
the molecular signatures characteristic of diseased chondrocytes,
an in-silico complementary approach to conventional compound
library screening. Here, we identify 19 molecules and 36 genes
with biological supportive evidence for validation as candidate
drugs in experimental models, such as that recently applied by Shi
et al. to demonstrate that the small molecule BNTA stimulates
expression of ECM components while supressing inflammatory
mediators in human osteoarthritic cartilage, an effect mediated
through superoxide dismutase 330.
Although these data demonstrate the context-specificity of
molecular indicators of disease, this work also has limitations.
Cartilage remains a difficult tissue to study at the molecular level,
given the low cell accessibility. The analyses were performed on
extracted tissues characterised by macroscopic grading using the
International Cartilage Repair Society (ICRS) scoring system32
and although all tissues were collected from weight-bearing areas
(i.e. mechanically-loaded), a degree of cell disease state hetero-
geneity is inevitable in the pooled sample collection. However, the
collection of both disease states from the same individual elim-
inates inter-individual variation as a source of confounding.
Finally, although these data represent the largest cohort of its
depth and kind in osteoarthritis, they are observational in nature.
Future biological experiments (e.g. by gene knock-out or over-
expression) will be key to prove which gene expression changes
are causal in disease development and progression. The genes
with convergent evidence from this study as well as osteoarthritis
GWAS are presented to help such research and accelerate the
pathway to translation.
In summary, by integrating multiple layers of omics data, we
have generated a first molecular QTL map for osteoarthritis-
relevant tissues and have helped resolve genetic association sig-
nals by identifying likely effector genes. We demonstrate how
integrating multi-omics data in primary human complex disease
tissue can serve as a valuable approach that moves from basic
discovery to accelerated translational opportunities. Our findings
identify drug repurposing opportunities and allow novel investi-
gational avenues for therapy development, responding to the
urgent clinical need of patients suffering from osteoarthritis.
Methods
Study participants. We collected tissue samples from 115 patients undergoing
total joint replacement surgery in 4 cohorts: 12 knee osteoarthritis patients (cohort
1; 2 women, 10 men, age 50–88 years, mean 68 years); 20 knee osteoarthritis
patients (cohort 2; 14 women, 6 men, age 54–82 years, mean 70 years); 13 hip
osteoarthritis patients (cohort 3; 8 women, 5 men, age 44–84 years, mean 62 years);
70 knee osteoarthritis patients (cohort 4; 42 women, 28 men, age 38–84 years,
mean 70 years).
All patients provided written, informed consent prior to participation in the
study. Matched low-grade and high-grade cartilage samples were collected from
each patient, while synovial lining samples were collected from patients in cohorts
2 and 4. All cartilage samples were collected from weight-bearing areas of the joint
to ensure that any differences observed between low- and high-grade cartilage
reflect disease progression stage rather than differential biomechanical stress.
Cohorts 1, 2, 4 (knee osteoarthritis). This work was approved by Oxford NHS REC
C (10/H0606/20 and 15/SC/0132), and samples were collected under Human
Tissue Authority license 12182, Sheffield Musculoskeletal Biobank, University of
Sheffield, UK.
We confirmed a joint replacement for osteoarthritis, with no history of
significant knee surgery (apart from meniscectomy), knee infection, or fracture,
and no malignancy within the previous 5 years. We further confirmed that no
patient used glucocorticoid use (systemic or intra-articular) within the previous
6 months, or any other drug associated with immune modulation. For cohort 1,
cartilage samples were scored using the OARSI cartilage classification system33,34.
From each patient, we obtained one sample with high OARSI grade signifying
high-grade degeneration ('high-grade sample'), and one cartilage sample with low
OARSI grade signifying healthy tissue or low-grade degeneration ('low-grade
sample').
For cohorts 2 and 4, cartilage samples were scored macroscopically using the
ICRS scoring system32. From each patient, we obtained one sample of ICRS grade 3
or 4 signifying high-grade degeneration ('high-grade sample'), and one cartilage
sample of ICRS grade 0 or 1 signifying healthy tissue or low-grade degeneration
('low-grade sample'). For cohorts 2 and 4, we also collected synovial membrane
from the suprapatellar region of the knee joint.
Finally, from all patients in cohorts 1, 2 and 4, we also obtained a blood sample
to extract DNA for genotyping.
Cohort 3 (hip osteoarthritis). Samples were collected under National Research
Ethics approval reference 11/EE/0011, Cambridge Biomedical Research Centre
Human Research Tissue Bank, Cambridge University Hospitals, UK.
We confirmed osteoarthritis disease status by examination of the excised
femoral head. From each patient, we obtained a cartilage sample showing a
fibrillated or fissured surface signifying high-grade degeneration ('high-grade
sample'), one cartilage sample showing a smooth shiny appearance signifying
healthy tissue or low-grade degeneration ('low-grade sample').
Isolation of chondrocytes. For cohorts 1, 2 and 4, we followed a previously
established protocol to isolate chondrocytes12 with the details as follows. Osteo-
chondral samples were transported in Dulbecco’s modified Eagle’s medium
(DMEM)/F-12 (1:1) (Life Technologies) supplemented with 2 mM glutamine (Life
Technologies), 100 U/ml penicillin, 100 μg/ml streptomycin (Life Technologies),
2.5 μg/ml amphotericin B (Sigma-Aldrich) and 50 μg/ml ascorbic acid (Sigma-
Aldrich) (serum free media). Half of each sample was then taken forward for
chondrocyte extraction. Cartilage was removed from the bone, dissected and
washed twice in 1xPBS. Tissue was digested in 3 mg/ml collagenase type I (Sigma-
Aldrich) in serum free media overnight at 37 °C on a flatbed shaker. The resulting
cell suspension was passed through a 70 μm cell strainer (Fisher Scientific) and
centrifuged at 400×g for 10 min. Subsequently, the cell pellet was washed twice in
serum free media and centrifuged at 400×g for 10 min. The resulting cell pellet was
resuspended in serum free media. Cells were counted using a haemocytometer and
the viability checked using trypan blue exclusion (Invitrogen). The optimal cell
number for spin column extraction from cells was between 4 × 106 and 1 × 107.
Cells were then pelleted and homogenised.
For cohort 3, the extraction of chondrocytes has previously been described35 in
the majority of these samples, with the remaining samples following the same
protocol. The protocol was based on that for cohorts 1, 2, 4 and highly similar as
described in the following. Each cartilage portion was minced with a scalpel and
placed in 20 ml of Dulbecco’s modified Eagle medium (Invitrogen) containing 10%
foetal bovine serum (Invitrogen) and 6 mgml−1 collagenase A (Sigma). The tissue
culture flasks were incubated overnight to digest the cartilage pieces. The resulting
cell suspension was passed through a 30 μm filter (Miltenyi) and centrifuged at
400×g for 10 min. The cell pellet was then re-suspended in 1 ml of PBS and counted
on a haemocytometer following 1:1 mixing with trypan blue to determine cell
viability.
Isolation of synoviocytes. We followed a previously established protocol to
process synovial samples36, with details as follows. Synovial samples were trans-
ported in serum free media, as described above. The synovial membrane was
dissected from underlying tissue then trypsinised for 1 h. Tissue was then digested
in 1 mg/ml Collagenase Blend H (Sigma Aldrich) in serum free media overnight at
37 °C on a flatbed shaker. The resulting cell suspension was passed through a 100
μm cell strainer (Fisher Scientific) and centrifuged at 400×g for 10 min. Subse-
quently, the cell pellet was washed twice in serum free media and centrifuged at
400×g for 10 min. The resulting cell pellet was resuspended in serum free media.
Cells were counted using a haemocytometer and the viability checked using trypan
blue exclusion (Invitrogen). The optimal cell number for spin column extraction
from cells was between 4 × 106 and 1 × 107. Cells were then pelleted and
homogenised.
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DNA, RNA and protein extraction. DNA, RNA, and protein extraction was
carried out using Qiagen AllPrep DNA/RNA/Protein Mini Kit following the
manufacturer’s instructions for cohorts 1, 2 and 4, with small variations for cohort
3 as previously described35 and recapitulated in the Supplementary Methods.
Samples were frozen at −80 °C (cohorts 1, 2, 4) or −70 °C (cohort 3) prior to
assays.
RNA sequencing. We performed a gene expression analysis on samples from 113
patients (Supplementary Data 7). We purified poly-A tailed RNA (mRNA) from
total RNA using Illumina’s TruSeq RNA Sample Prep v2 kits. We then fragmented
the mRNA using metal ion-catalysed hydrolysis and synthesised a random-primed
cDNA library. The resulting double-strand cDNA was used as the input to a
standard Illumina library prep, whereby ends were repaired to produce blunt ends
by a combination of fill-in reactions and exonuclease activity. We performed A-
tailing to allow samples to be pooled, by adding an ‘A' base to the blunt ends and
ligation to Illumina Paired-end Sequencing adaptors containing unique index
sequences. Due to better performance, the 10-cycle PCR amplification of libraries
was carried out using KAPA Hifi Polymerase. A post-PCR Agilent Bioanalyzer was
used to quantify samples, followed by sample pooling and size-selection of pools
using the LabChip XT Caliper. The multiplexed libraries were sequenced on the
Illumina HiSeq 2000 for cohort 1 and HiSeq 4000 for cohorts 2–4 (75 bp paired-
ends). Sequenced data underwent initial analysis and quality control (QC) on reads
as standard. The sequencing depth was similar across samples, with 90% of samples
passing final QC (see below) having 87.2–129.2 million reads.
Proteomics. Proteomics analysis was performed on cartilage samples from 103
patients (Supplementary Data 7).
For cohort 1, all steps of protein digestion, 6-plex TMT labelling, peptide
fractionation and LC-MS analysis on the Dionex Ultimate 3000 UHPLC system
coupled with the high-resolution LTQ Orbitrap Velos mass spectrometer (Thermo
Scientific), were previously described12 and are recapitulated in the Supplementary
Methods. The sample preparation protocol formed the basis of processing for
cohorts 2–4 using 10-plex TMT labelling and an Orbitrap Fusion Tribrid Mass
Spectrometer (Thermo Scientific) with otherwise only minor alterations as
described in the Supplementary Methods.
Genotyping. We used Illumina HumanCoreExome-12v1-1 for genoting cohort 1
and Illumina InfiniumCoreExome-24v1-1 for genotyping cohort 2–4 patients.
Quantification of RNA levels. We used samtools v1.3.137 and biobambam
v0.0.19138 to convert cram to fasq files after exclusion of reads that failed QC. We
applied FastQC v0.11.5 to check sample quality39 and excluded nine samples
(Supplementary Data 7).
We obtained transcript-level quantification using salmon 0.8.240 (with–gcBias
and –seqBias flags to account for potential biases) and the GRCh38 cDNA
assembly release 87 downloaded from Ensembl [http://ftp.ensembl.org/pub/
release-87/fasta/homo_sapiens/cdna/]. We used tximport41 to convert transcript-
level to gene-level scaled transcripts per million (TPM) estimates, with estimates
for 39,037 genes based on Ensembl gene IDs.
We excluded four samples due to low mapping rate (<80%), three samples due
to non-European ancestry recorded in the clinic, 18 samples due to low RIN (<5),
two samples as duplicates, eight samples due to abnormal gene read density plots
(detected separately in cartilage and synovium for three cartilage and five synovium
samples; all exclusions are listed in Supplementary Data 7).
The final gene expression dataset included 259 samples (Supplementary Fig. 1;
87 patients’ low-grade and 95 high-grade cartilage samples with 15,249 genes that
showed counts per million (CPM) of ≥1 in ≥40 samples, and 77 patients’ synovium
samples with 16,004 genes that showed CPM ≥1 in ≥20 samples).
Quantification of protein levels. To carry out protein identification and quan-
tification, we submitted the mass spectra to SequestHT search in Proteome Dis-
coverer 2.1. The precursor mass tolerance was set at 30 ppm (Orbitrap Velos data,
cohort 1) or 20 ppm (Fusion data, cohorts 2–4). For the CID spectra, we set the
fragment ion mass tolerance to 0.5 Da; for the HCD spectra, to 0.02 Da. Spectra
were searched for fully tryptic peptides with maximum two miss-cleavages and
minimum length of six amino acids. We specified static modifications as TMT6plex
at N-termimus, K and Carbamidomethyl at C; dynamic modifications included
deamidation of N,Q and oxidation of M. For each peptide, we allowed for a
maximum two different dynamic modifications with a maximum of two repeti-
tions. We used the Percolator node to estimate peptide confidence. We set the
peptide FDR at 1% and based validation on the q value and decoy database search.
We searched all spectra against a UniProt fasta file that contained 20,165 reviewed
human entries. The Reporter Ion Quantifier node included a TMT-6plex (Velos
data, cohort 1) or TMT-10plex (Fusion data, cohorts 2–4) custom Quantification
Method with integration window tolerance at 20 or 15 ppm, respectively. As
integration methods, we used the Most Confident Centroid at the MS2 or MS3
level. We only used peptides uniquely belonging to protein groups for
quantification.
We excluded samples from four patients due to non-European ancestry
(Supplementary Data 7). The final dataset included low-grade and high-grade
cartilage samples each from 99 patients, with 4801 proteins was observed in ≥30%
of samples, and 1677 proteins in all samples, in line with the resolution depth of the
isobaric labelling method employed. To account for protein loading, abundance
values were normalised by the sum of all protein abundances in a given sample,
then log2-transformed and quantile normalised.
Genotype analysis and QC. Genotypes were called using GenCall (Illumina) and
mapped to GRC37/hg19 using online tools (http://www.well.ox.ac.uk/~wrayner/
strand/index.html). QC was carried out using the same method for both arrays.
Briefly, we performed a pre-filtering step to exclude samples and variants with a
call rate <90%. Sample QC included identity checks correlating the array genotypes
to Fluidigm genotypes obtained at sample reception (no samples had a con-
cordance <0.95). We excluded samples based on call rate <98%, heterozygosity
distribution outliers performed using two different minor allele frequency (MAF)
bins (≥1% MAF and <1% MAF) and sex discrepancies. We performed pairwise
identity by descent (IBD) in PLINK42,43 after filtering out variants with MAF < 1%
and carrying out linkage disequilibrium based pruning using R2 0.2. We retained
only patients with pairwise PI_HAT ≤ 0.2. To look at ethnicity we combined all
patients from both arrays with data from the 1000 Genomes Project individuals
(https://www.internationalgenome.org)44. We included overlapping variants only
and conducting IBD, as described above, followed by multidimensional scaling
using PLINK. Visual ethnic outliers were excluded following examination of the
first two components. Variants were excluded if call rate <98% and/or
Hardy–Weinberg p value (pHWE) <1 × 10−4. The final datasets contained 12
patients and 534,694 variants and 99 patients and 527,717 variants for cohorts 1
and 2–4, respectively.
Prior to imputation, all genotypes were combined into a single dataset
containing 111 patients and 504,235 overlapping variants. Further QC was
performed to exclude any variants with strand, position and allele frequency
differences compared to the HRC panel45 using a HRC preparation checking tool
(http://www.well.ox.ac.uk/~wrayner/tools/; v4.2.7). The resulting dataset contained
111 patients and 389,511 variants. We imputed up to HRC panel (v1.1 2016) using
the Michigan imputation server (https://imputationserver.sph.umich.edu/index.
html)46 with Eagle2 (v2.3) phasing. Post-HRC imputation we used a post-
imputation data checking programme (http://www.well.ox.ac.uk/~wrayner/tools/
Post-Imputation.html; v1.0.2) to visualise the results and we excluded variants with
poor imputation quality (R2 < 0.3) and pHWE <1 × 10−4. We excluded two
patients due to absence of RNA and protein data. The resulting final dataset
contained 10,249,108 autosomal variants and 109 patients.
Identification of cis-eQTLs. For each gene, we considered genetic variants within
1 Mb of the transcription start site (TSS) (definition see below), and followed a
similar method to GTEx9,47 as follows.
For each tissue, we included only genes with ≥1 count per million in at least
20% samples and we normalised between samples using TMM (weighted trimmed
mean of M values)48 implemented in edgeR49. To facilitate cartilage comparisons
post-analysis, the previous two steps (exclusions of low expressed genes and the
between sample normalisation) were performed with high-grade and low-grade
cartilage samples combined. For each tissue separately, we then normalised across
samples using an inverse normalisation transformation for each gene. To infer
hidden factors associated with cohort, sequencing batch, or other technical
differences, we applied probabilistic estimation of expression residuals (PEER)50
separately to each tissue (PEER C++ version with standard parameters from the
R version, i.e. iteration= 1000, bound= 0.001, variance= 0.00001, Alpha a=
0.001, Alpha b= 0.1, Eps a= 0.1, Eps b= 10). We used the GTEx modified version
of FastQTL51 (https://github.com/francois-a/fastqtl; v6p), which allows for minor
allele count filtering, reporting of MAF and calculation of FDR. We determined the
TSS for each gene using empirical transcript level expression information from
synovium, high-grade and low-grade cartilage samples (see below) and defined the
cis-mapping region to be 1 Mb in either direction from the TSS. We restricted the
analysis to variants with minor allele count of at least 10 in a given tissue. Nominal
p values for each gene-variant pair were based on linear regression, including 15
PEER factors for the given tissue, sex and genotype array as covariates. We then
employed the adaptive permutation scheme with the—permute 1000 10000 option
to generate empirical p values. Genes with significant eQTLs ('eGenes') were
defined at the 5% Storey–Tibshirani FDR using the q values generated from the
empirical p values52. For each eGene, significant eQTLs were defined as variants
with nominal p value below the nominal p value threshold for that gene generated
in FastQTL.
The normalised effect size (NES) of the eQTL is reported for the alternate allele
according to GRC37/hg19.
Identification of cis-pQTLs. We followed a similar protocol as for cis-eQTL
analysis, also considering genetic variants within 1Mb of the TSS (definition see
below). For low-grade and high-grade cartilage, we included 1677 proteins that
were measured across all samples. We normalised across samples using an inverse
normalisation transformation for each gene separately in each tissue. To account
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for possible technical variation, we used PEER50 (with parameters as for the eQTL
analysis above) and included 26 PEER factors, sex and genotype array as covariates
using the GTEx modified version of FastQTL (https://github.com/francois-a/
fastqtl; v6p). We used the TSS established for the eQTL analysis, yielding a unique
mapping for 1461 proteins, which were then taken forward. For each protein, we
considered variants within a 1Mb region in either direction from the TSS,
restricting further to minor allele count of 10 or higher. We then followed the same
procedure as for cis-eQTLs to identify variant-protein pairs with significant cis-
pQTL effects.
We carried out a protein–protein network analysis for the proteins with
significant pQTL effects using the STRING v11.0 database53 (https://string-db.org/;
see Supplementary Note 1).
Sensitivity analysis for cis-eQTLs and cis-pQTLs. For both eQTLs and pQTLs,
we verified that the results were robust by carrying out a sensitivity analysis
including patient age and osteoarthritis joint (knee or hip) as covariates in addition
to the PEER factors, sex and array (see Supplementary Note 1).
Transcription start site (TSS) definition. To determine which transcript to use to
define the TSS for each gene, we established the most abundant transcript for each
gene. To have the same definition across all tissues, we analysed cartilage and
synovium tissues jointly, considering 16,886 genes that passed quantification QC in
at least one tissue (based on 15,249 genes in cartilage and 16,004 genes in syno-
vium). For each transcript, we calculated the expression in each sample as scaled
TPM using tximport41. For each gene, we then obtained the most abundant
transcript in each tissue in each patient, and calculated the proportion of samples
in which each transcript was the most abundant. The transcript that was the most
abundant in the largest proportion of samples was used to define the TSS for the
gene. For genes in which more than one transcript was the most abundant, we
chose one of the most abundant transcripts at random to define the TSS.
Across all genes, 47.9% had the same most abundant transcript in at least 90% of
samples in both cartilage and synovium; 71% of genes had the same most abundant
transcript in 60% of samples in cartilage and synovium. We mapped the most
abundant transcript (using the ENST identifier) to GRCh37 using ftp://ftp.ensembl.
org/pub/grch37/release-87/gtf/homo_sapiens/Homo_sapiens.GRCh37.87.chr.gtf.gz.
For 93 transcripts, ENSG identifiers differed between the builds, therefore genes
were identified by a composite ID in the format GeneName(b37)_ENSG. We
excluded 1940 transcripts with missing start or end positions (largely in patched
genome build regions), and ~500 transcripts mapped to chromosomes X, Y or
mitochondrial DNA, we established the TSS for 13,180 autosomal genes included in
the cartilage and 13,708 genes included in the synovium molQTL analysis.
Differential gene regulation in low-grade and high-grade cartilage. To identify
differential regulation of gene expression between high- and low-grade cartilage, we
used Meta-Tissue v0.554 (downloaded from http://genetics.cs.ucla.edu/metatissue/
index.html), which implements METASOFT55. The m value calculated by
METASOFT for gene-variant pair in each tissue provides a posterior probability (m
value) of an effect in that tissue. Consequently, we aimed to identify eQTLs present
in one tissue (defined as m > 0.9), and absent in the other (defined as m < 0.1). We
note that there were no cis-eQTLs present in both tissues (m > 0.9) with opposing
direction of effect.
Meta-Tissue restricts covariates input to the same values for each patient across
tissues, while different PEER covariates were provided for each tissue in the
FastQTL analysis. Hence, for each tissue, we obtained residuals from regressing the
normalised expression data on the 15 PEER factors, sex and array, then used the
residuals as input for Meta-Tissue. We included genotype dosages based on both
the low- and high-grade results for each analysis. We ran METASOFT using the
default settings provided in the output script from Meta-Tissue. We only
considered eQTLs that were identified in the FastQTL analysis in the appropriate
tissue. To identify variants located in regulatory regions, we used Ensembl Variant
Effect Predictor (http://grch37.ensembl.org/Homo_sapiens/Tools/VEP/). For 32
genes with differential QTLs, we considered gene annotations from several sources:
using Gene Ontology biological process terms, through gene annotations in
GOSeq56 (accessed on 31 May 2020), and from the summaries and functions
sections on GeneCards gene pages (https://www.genecards.org, accessed 3
June 2020).
We also carried out a formal enrichment analysis of the 32 genes using GoSeq
(see Supplementary Note 2).
Co-localisation between molecular QTLs (molQTLs) and osteoarthritis GWAS
associations. To examine co-localisation between molQTLs and GWAS associa-
tions, we used genome-wide summary statistics from the largest osteoarthritis
meta-analysis to date, based on UK Biobank and arcOGEN data8. We analysed all
64 genome-wide significant signals using coloc57, separately for each tissue and
omics level.
In the co-localisation analysis for each signal, we considered the region spanning
100 kb either side of the index variants. If that region overlapped any genes with
significant cis-eQTLs or cis-pQTLs, we extended the region to encompass all
variants included in the molQTL analysis for these genes. To formally obtain a
posterior probability for co-localisation, we used coloc.fast (https://github.com/
tobyjohnson/gtx/blob/526120435bb3e29c39fc71604eee03a371ec3753/R/coloc.R), a
Bayesian statistical test which implements the coloc57 method. We used the default
settings for coloc.fast. We considered a 80% posterior probability of GWAS and
molQTL shared association at a single variant ('PP4 ≥ 0.8') to indicate evidence of
co-localisation.
Differential RNA expression between high-grade and low-grade cartilage. We
tested differential expression of 15,249 genes between high-grade and low-grade
cartilage using paired samples from 83 patients. To detect robust gene expression
differences, we carried out analyses using different software packages as recom-
mended in a landmark survey of best practices58, applying limma59, edgeR60 and
DESeq261. We also tested five analysis designs with different options to account for
technical variation, including SVAseq62. In particular, we tested for differential
expression using
(1) a paired analysis of intact and degraded samples (i.e. specifying patient ID as
covariate);
(2) a paired analysis of intact and degraded samples, with ten additional
covariates accounting for technical variation identified by SVAseq62;
(3) a paired analysis of intact and degraded samples, with ten RNA sequencing
batches as covariates;
(4) an unpaired analysis of intact and degraded samples;
(5) an unpaired analysis of intact and degraded samples, with 19 additional
covariates accounting for technical variation identified by SVAseq.
We tested for differential expression using the following R packages:
(i) limma59 (with lmFit and eBayes), after applying limma-voom63 to remove
heteroscedasticity;
(ii) DESeq261, separately with and without outlier filtering/replacement
(minReplicatesForReplace= Inf, cooksCutoff= FALSE options);
(iii) edgeR60, using the likelihood ratio test (glmFit and glmLRT functions), and
separately, using the F test (glmQLFit and glmQLFTest functions).
Here and elsewhere, we used Ensembl38p10 to identify genes with uniquely
corresponding Ensembl gene ID and gene name (13,737 of 15,249 genes in the
RNA data).
In each analysis design and method, we used a 5% FDR threshold to correct for
multiple testing. As the final step, we applied a conservative approach and
considered a gene ‘significantly differentially expressed' between low-grade and
high-grade cartilage if it showed significant differential expression across all
analysis designs and testing methods (2557 genes, including 2418 with uniquely
corresponding Ensembl gene ID and gene name). As discussed in the
Supplementary Note 3, for each analysis design, the number of significant genes at
5% FDR was similar across all tests.
Furthermore, we have performed a sensitivity analysis testing differential
expression based on the patients in cohort 4 only and verified that results were
highly consistent with the analysis of all patients (see Supplementary Note 3).
We used the pheatmap v1.0.12 function in R to plot the gene expression for the
20 genes with the highest absolute log-fold differences between high-grade and
low-grade cartilage (selected from 290 genes with significant and concordant cross-
omics differences, see Supplementary Methods).
Differential protein abundance between high-grade and low-grade cartilage.
We performed differential analysis for 4801 proteins that were measured in ≥30%
of patients, applying limma59 to paired samples from 99 patients. Significance was
defined at 5% FDR to correct for multiple testing, yielding 2233 proteins with
significant differential abundance (2019 proteins with uniquely corresponding
Ensembl gene ID and gene name).
As batch effects in proteomics data can be pervasive64,65, paired samples from
any patient were always assayed in the same 6-plex (cohort 1) or 10-plex (cohorts
2–4). As a sensitivity analysis, we carried out a differential abundance analysis for
the proteomics data with explicit adjustment for the plexes, to confirm that
adjustment for patient effects was captured between-plex batch effects. For each
protein, we calculated the log2 of normalised abundance values plus 1. We then
obtained residuals from linear regression of these values on the 13 batches used in
the proteomics data. These residuals were quantile normalised. We then used
limma to test for differential abundance between low-grade and high-grade
cartilage using the quantile normalised residuals, applying a paired design and the
same method as in the main analysis. The results were highly similar to the main
analysis (see Supplementary Note 4).
We used the pheatmap v1.0.12 function in R to plot the abundance of the 20
proteins with the highest absolute log-fold differences between high-grade and low-
grade cartilage (selected from 290 genes with significant and concordant cross-
omics differences, see Supplementary Methods).
Replication of differences between high-grade and low-grade cartilage. We
used an independent dataset from the RAAK study (35 osteoarthritis patients, of
which 28 knee, 7 hip osteoarthritis) to replicate the molecular differences between
high-grade and low-grade cartilage. The RAAK dataset and analysis were taken
from a previous publication15. Briefly, mRNA samples were sequenced on Illumina
HiSeq 2000/4000 (paired-end 2 × 100 bp RNA-sequencing), aligned using
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GSNAP66, and quantified using HTSeq67. We used the differential expression
analysis as originally published15, based on DESeq2, with removal of batch effects
using the function removeBatchEffect from the limma R package, then application
of a general linear model assuming a negative binomial distribution and a paired
Wald-test between preserved and lesioned OA cartilage samples. The data were
downloaded from the Github repository https://git.lumc.nl/rcoutinhodealmeida/
miRNAmRNA on 20 June 2020. The analysis as published included 20,165 genes,
of which 2387 were differentially expressed at 5% FDR. Of these genes, 12,663 had
uniquely mapping Ensembl gene ID and gene name and were also assayed in our
data (including 1830 genes with significant differential expression at 5% FDR in the
RAAK study). For the genes with RNA-level, protein-level or cross-omics level
differential expression in the discovery analysis above, we calculated the proportion
with concordant direction of effect in the RAAK data, and applied Fisher’s test to
determine whether this proportion was higher than for other genes (RNA-level:
compared to all genes not differentially expressed; protein- and cross-omics level:
compared to all genes not differentially expressed, but assayed in proteomics). We
also calculated the proportion of genes with p < 0.05 and FDR < 5% in the RAAK
analysis, and the proportion of these with concordant direction of effect.
Pathway associations for differences between high-grade and low-grade
cartilage. To identify the biological processes with significant molecular differ-
ences between high-grade and low-grade cartilage, we carried out gene set
enrichment analyses based on the differential expression on RNA, protein and
cross-omics levels. We tested for association of the differentially expressed (DE)
genes on RNA and/or protein levels at 5% FDR, with robustness checks using more
stringent FDR thresholds (1, 0.5 and 0.1%). We restricted this analysis to genes
with unique mapping between Ensembl gene ID and Gene Name in
Ensembl38p10, and Ensembl gene ID and Entrez ID in HUGO (https://www.
genenames.org/ accessed 05/03/2018; 13,094 genes measured on RNA level, 4390
genes measured on protein level, 4387 genes measured on both RNA and protein
levels).
We applied Signalling Pathway Impact Analysis (SPIA)68 to test for association
with KEGG signalling pathways. SPIA combines enrichment p values with
perturbation impact on the pathway based on log-fold differences of the DE genes;
perturbation p values are obtained by bootstrapping. Enrichment and perturbation
p values were combined using a normal inversion method which only gives low p
values when both over-representation and pathway impact p values are low
(function option combine= 'norminv'). Significance of pathway association was
defined as a threshold of 5% FDR applied to the combined p values in each analysis.
For the analysis of genes DE on both RNA and protein levels, we carried out tests
using the log-fold differences from the RNA data (based on the limma analysis with
paired samples and SVAseq covariates), and separately, from the protein data.
We also tested enrichment in Gene Ontology terms using GOseq56, separately
for genes with higher or lower expression in high-grade compared to low-grade
cartilage. We accounted for gene length (pwf function options ‘hg19' and
‘geneSymbol'). Significance was defined as a threshold of 5% FDR in each analysis.
The results showed broad agreement with the results of the SPIA analysis (see
Supplementary Note 5 and Supplementary Data 3).
Identification of genes with osteoarthritis GWAS gene-level association.
From the recent UK Biobank and arcOGEN GWAS meta-analysis8, we obtained
the results of a gene-level analysis for each of the four osteoarthritis phenotypes
(self-reported plus hospital diagnosed, hospital diagnosed knee or hip, hospital
diagnosed knee, hospital diagnosed hip), as described in the GWAS paper. Briefly,
this analysis used MAGMA v1.0669 and was based on the mean SNP log-p-value in
the gene, accounting for LD.
To calculate the effective number of tests across phenotypes, we calculated the
correlation matrix between the gene p values for the four osteoarthritis phenotypes,
and obtained the eigenvalues of this matrix. The effective number of tests Neff for
phenotypes was then calculated as Neff ¼ N 
P
λ Iðλ>1Þ*ðλ 1Þ, where N= 4 is
the number of phenotypes, and λ denotes the eigenvalues. Across the Pearson and
Spearman correlation matrices, we obtained Neff < 2.65. With 18,449 genes per
phenotype, the significance threshold for gene-level p values across genes and
phenotypes was thus set as 0.05/(18,449 × 2.65)= 1.02 × 10−6.
After accounting for the effective number of tests across phenotypes and genes
using a Bonferroni correction, 320 of 18,449 genes showed significant association
with at least one phenotype. Of these genes, 238 genes were compared between
low-grade and high-grade cartilage on at least one omics level and had uniquely
corresponding Ensembl gene ID and gene name.
ConnectivityMap analysis. To identify opportunities for drug repurposing, we
used ConnectivityMap17 to identify compounds and perturbagen classes (PCLs)
that could possibly reverse the differences identified between high-grade and low-
grade cartilage. Using the online interface clue.io (accessed 3 March 2019), we
submitted the 148 genes with significantly higher expression on both RNA and
protein level to calculate a ‘tau’ connectivity score to gene expression signatures
experimentally induced by various perturbations in nine cell lines. A positive tau
score indicates similarity between the gene expression signature of a perturbation
and the submitted query (i.e. upregulation of the genes with higher expression in
high-grade compared to low-grade cartilage). A negative tau score indicates that
gene expression signature of a perturbation opposes the submitted query (i.e.
downregulation of the genes with higher expression in high-grade compared to
low-grade cartilage). Recommended thresholds for further consideration of results
are tau of at least 90, or below −90, respectively (https://clue.io/connectopedia/
connectivity_scores, accessed 3 March 2019). A total of 2837 compound and 171
PCL perturbations were evaluated in clue.io. We shortlisted perturbations where
both the summary tau and the median tau across cell lines were higher than 90 or
lower than −90 for PCLs, with more conservative thresholds of higher than 95 or
lower than −95 for compounds. The clue.io platform also contained perturbation
data from 3799 gene knock-down and 2160 over-expression experiments (with
2111 genes in both, i.e. 3848 genes total). These data were used to shortlist genes
where both the summary and median tau were higher than 95 or lower than −95.
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA sequencing data reported in this paper have been deposited to the EGA
(accession numbers EGAD00001005215, EGAD00001003355, EGAD00001003354,
EGAD00001001331. The proteomics data reported in this paper have been deposited to
PRIDE (accession numbers PXD014666, PXD006673, PXD002014. The genotype data
reported in this paper have been deposited to the EGA (accession numbers
EGAD00010001746, EGAD00010001285, EGAD00010001292, EGAD00010000722.
Data from the 1000 Genomes Project are publicly available (https://www.
internationalgenome.org). We also used publicly available data on osteoarthritis
differential gene expression from the RAAK Study (https://git.lumc.nl/
rcoutinhodealmeida/miRNAmRNA, accessed 20 June 2020).
Further data including the TSS information, all significant molQTLs and full co-
localisation results, can be obtained online from https://hmgubox.helmholtz-muenchen.
de/d/fc1fcf65a6724152b7f9/. The full molecular QTL data and molecular differences
between high-grade and low-grade cartilage are available through the Downloads page of
the Musculoskelatal Knowledge Portal (mskkp.org).
Code availability
All software used in this study is available from free repositories or from manufacturers
as referenced in the Methods section.
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